3618-03-9

Usage

Uses

Used in Pharmaceutical Research:
Cyclohexanecarboxylic acid, 4-hydroxy-, methyl ester, cisis used as a building block in pharmaceutical research for the synthesis of various pharmaceuticals and biologically active molecules. Its unique structure and cis configuration contribute to the development of innovative drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, Cyclohexanecarboxylic acid, 4-hydroxy-, methyl ester, cisserves as an essential intermediate for the preparation of complex organic compounds. Its reactivity and structural features enable the synthesis of a wide range of molecules with diverse applications in various industries.
Used in Drug Development:
Cyclohexanecarboxylic acid, 4-hydroxy-, methyl ester, cisis employed in drug development as a key component in the design and synthesis of new pharmaceutical agents. Its unique properties and versatility in chemical reactions allow researchers to explore its potential in creating novel therapeutics with improved efficacy and selectivity.
Used in Chemical Research:
In chemical research, Cyclohexanecarboxylic acid, 4-hydroxy-, methyl ester, cisis utilized to study the effects of stereochemistry on the reactivity and properties of organic compounds. Its cis configuration provides valuable insights into the role of spatial arrangement in chemical reactions and the development of new synthetic strategies.
Overall, Cyclohexanecarboxylic acid, 4-hydroxy-, methyl ester, cisis a versatile and valuable compound in various fields, including pharmaceutical research, organic synthesis, drug development, and chemical research. Its unique structure and properties make it an essential component in the creation of innovative and effective therapeutic agents.

Upstream product

• 99-76-3 methyl 4-hydroxylbenzoate 
• 3685-26-5 trans-4-hydroxycyclohexanecarboxylic acid 
• 67-56-1 methanol 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 99-96-7 4-hydroxy-benzoic acid 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 3685-26-5 cis-4-hydroxycyclohexanecarboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 874-61-3 4-oxocyclohexanecarboxylic acid 

Downstream Products

• 1160960-65-5 C₅₆H₅₇N₁₃O₁₁S₆ 
• 1160960-69-9 C₁₇H₃₂O₃Si 
• 1160960-70-2 C₂₀H₃₆O₅Si 
• 1160960-71-3 C₂₀H₃₈O₅Si 
• 1160960-72-4 C₁₄H₂₄O₅ 
• 145912-67-0 (trans)-methyl 4-((tert-butyldimethylsilyl)oxy)cyclohexanecarboxylate 
• 1239311-08-0 methyl cis-4-[4-(5-cyclopentyloxymethyl[1.3.4]thiadiazol-2-ylcarbamoyl)phenoxy]cyclohexanecarboxylate 
• 1239311-06-8 cis-4-[4-(5-cyclopentyloxymethyl[1,3,4]thiadiazol-2-ylcarbamoyl)phenoxy]cyclohexanecarboxylic acid 
• 1239310-91-8 cis-4-(4-methoxycarbonylcyclohexyloxy)benzoic acid 
• 1239311-09-1 methyl cis-4-(4-chlorocarbonylphenoxy)cyclohexanecarboxylate 
• 1239311-10-4 methyl cis-4-(4-isothiocyanatocarbonylphenoxy)cyclohexane-carboxylate 
• 1239310-90-7 tert-butyl cis-4-(4-methoxycarbonylcyclohexyloxy)benzoate 

Relevant academic research and scientific papers

Trans-Selective and Switchable Arene Hydrogenation of Phenol Derivatives

A trans-selective arene hydrogenation of abundant phenol derivatives catalyzed by a commercially available heterogeneous palladium catalyst is reported. The described method tolerates a variety of functional groups and provides access to a broad scope of trans-configurated cyclohexanols as potential building blocks for life sciences and beyond in a one-step procedure. The transformation is strategically important because arene hydrogenation preferentially delivers the opposite cis-isomers. The diastereoselectivity of the phenol hydrogenation can be switched to the cis-isomers by employing rhodium-based catalysts. Moreover, a protocol for the chemoselective hydrogenation of phenols to cyclohexanones was developed.

Dihydropyrimidine compound and uses of dihydropyrimidine compound in drugs

The present invention relates to a dihydropyrimidine compound and uses of the dihydropyrimidine compound as drugs, particularly as drugs for treatment and prevention of hepatitis B, particularly to acompound represented by a general formula (I) or (Ia) or an enantiomer, a diastereomer, a tautomer, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein each variable is definedin the specification. The invention further relates to uses of the compound represented by a general formula (I) or (Ia) or the enantiomer, the diastereomer, the tautomer, the hydrate, the solvate orthe pharmaceutically acceptable salt thereof as drugs, especially as drugs for treatment and prevention of hepatitis B. The formulas (I) and (Ia) are defined in the specification.

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, provided herein is a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES

The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma

Herein we describe the discovery and characterization of a novel, piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) with a core structure distinct from other reported CETP inhibitors. A versatile synthesis starting from 4-methoxypyridine enabled an efficient exploration of the SAR, giving a lead molecule with potent CETP inhibition in human plasma. The subsequent optimization focused on improvement of pharmacokinetics and mitigation of off-target liabilities, such as CYP inhibition, whose improvement correlated with increased lipophilic efficiency. The effort led to the identification of an achiral, carboxylic acid-bearing compound 16 (TAP311) with excellent pharmacokinetics in rats and robust efficacy in hamsters. Compared to anacetrapib, the compound showed substantially reduced lipophilicity, had only modest distribution into adipose tissue, and retained potency in hypertriglyceridemic plasma in vitro and in vivo. Furthermore, in contrast to torcetrapib, the compound did not increase aldosterone secretion in human adrenocortical carcinoma cells nor in chronically cannulated rats. On the basis of its preclinical efficacy and safety profile, the compound was advanced into clinical trials.

A nitric oxide-dexamethasone and preparation method and use thereof

The invention relates to nitric oxide donor type hexadecadrol as well as a preparation method and application thereof. The nitric oxide donor type hexadecadrol as a compound is obtained by enabling nitrous acid ester to be connected with hexadecadrol through ethyl cyclohexanecarboxylate; the in-vitro antiinflammatory activity of the nitric oxide donor type hexadecadrol is better than that of the hexadecadrol; besides, the nitric oxide donor type hexadecadrol can restrain the growth of methicillin-resistant staphylococcus aureus (MRSA) in vitro, restrain the formation of MRSA biomembrane, and lead to the death of bacteria in the MRSA biomembrane. In addition, the compound can notably increase the survival rate of mice in MRSA sepsis lethal models, reduces the inflammation pathology damage of the mice in sub-sepsis models, decreases the constant value number of bacteria, and has notable advantages in the respect of preventing and treating MRSA sepsis.

SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

PYRROLO PYRIMIDINE DERIVATIVE

The compound represented by general formula (I) has strong Axl inhibition activity by means of a pyridone ring structure being introduced into a pyrrolo pyrimidine skeleton, and so the result can serve as a treatment agent for Axl-related diseases, for example cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors, renal disease, immune system disorders, and cardiovascular disease.

NOVEL CARBOXYLIC ACID COMPOUNDS USEFUL FOR INHIBITING MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1

The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salts, thereof, where R, X, A, E, and G are as described herein, methods of preparing the compounds, and use of the compounds to treat pain and/or inflammation.